Table 5 Other designing strategies of small-molecule compounds for modulating ncRNAs
From: Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy
Method | Compound | Name | Target | Structure | Cancer type | References |
|---|---|---|---|---|---|---|
Pharmacological validation | 22 | Bisphenol-A (BPA) | LncRNA (HOTAIR) |
| Breast cancer | [125] |
23 | Diethylstilbestrol (DES) |
| ||||
24 | 3-(4-amino-1H-benzo[d]imidazole-2-carboxamido)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | CircRNAs:cirbap2, circCdr1, circZNF292, circHIPK3, circTCF25, LncRNAs: H19, HULC DQ786243, HOXD-AS1, CCAT1 |
| Glioma, Breast cancer | [126] | |
25 | 2-O-methylmagnolol | LncRNA GAS5 |
| Skin cancer | [129] | |
26 | Honokiol | MiR-21 |
| Osteosarcoma | [130] | |
27 | Curcumin | MiR-21 |
| Osteosarcoma | [131] |
